Greenland Mines Secures Additional 180-Day Period for Nasdaq Bid Price Compliance

Rhea-AI Summary

Greenland Mines (Nasdaq: GRML) said Nasdaq granted an additional 180-day extension, through September 14, 2026, to regain compliance with the minimum bid price requirement. The extension reflects Nasdaq's finding that the company meets other listing standards, including market value of publicly held shares. The company must reach a $1.00 closing bid for 10 consecutive business days during the compliance period to regain compliance and avoid delisting.

Greenland Mines reiterated its commitment to maintaining its Nasdaq listing while advancing development of its mineral resources and cell and gene therapy assets.

Positive

• Nasdaq granted a 180-day compliance extension through September 14, 2026
• Nasdaq found the company meets other listing standards including market value of publicly held shares

Negative

• Must achieve a $1.00 closing bid for 10 consecutive business days to regain compliance
• Failure to meet the bid-price requirement by September 14, 2026 could lead to delisting proceedings

News Market Reaction – GRML

+3.36%

12 alerts

+3.36% News Effect

+17.3% Peak Tracked

-3.2% Trough Tracked

+$2M Valuation Impact

$47.50M Market Cap

0.6x Rel. Volume

On the day this news was published, GRML gained 3.36%, reflecting a moderate positive market reaction. Argus tracked a peak move of +17.3% during that session. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $47.50M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights that Greenland Mines obtained an additional 180-day period, through Sep...

Analysis

This announcement highlights that Greenland Mines obtained an additional 180-day period, through September 14, 2026, to regain compliance with Nasdaq’s $1.00 minimum bid price requirement over 10 consecutive business days. It confirms the company met all other listing standards, including market value of publicly held shares. In context, investors typically watch progress on strategic mineral and cell and gene therapy assets alongside steps taken to close the gap between the current price and the bid-price threshold.

Key Figures

Extension period: 180 days Minimum bid price: $1.00 per share Compliance streak: 10 business days +5 more

8 metrics

Extension period 180 days Additional Nasdaq bid-price compliance window through September 14, 2026

Minimum bid price $1.00 per share Required closing bid for at least 10 consecutive business days

Compliance streak 10 business days Required consecutive days at or above $1.00 bid

Share price $0.4021 Pre-news price vs $1.00 Nasdaq minimum bid requirement

Daily price change 14.54% 24-hour price change prior to this announcement

Today’s volume 2,603,926 shares Compared with 20-day average volume of 2,204,040

52-week range high $0.5269 52-week high price level

200-day MA $0.39 Pre-news long-term moving average level

Historical Context

1 past event · Latest: Mar 19 (Positive)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 19	Environmental program launch	Positive	-4.5%	Engaged WSP Denmark for multi-year EIA baseline work at Skaergaard project.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited history in the last six months; prior operational update saw a -4.46% reaction despite project advancement.

Recent Company History

Recent news for Greenland Mines includes a Mar 19, 2026 announcement engaging WSP Denmark for a comprehensive Environmental Impact Assessment baseline program at the Skaergaard project, supporting a future exploitation license application. That operationally positive update coincided with a -4.46% 24-hour price move. Today’s Nasdaq bid-price compliance extension focuses on maintaining the listing while development of strategic mineral and cell and gene therapy assets continues, following on from that project-focused progress.

Key Terms

minimum bid price requirement, nasdaq listing requirements, market value of publicly held shares, cell and gene therapy

4 terms

minimum bid price requirement regulatory

"to regain compliance with Nasdaq's minimum bid price requirement."

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

nasdaq listing requirements regulatory

"continued compliance with all other applicable Nasdaq listing requirements"

NASDAQ listing requirements are the financial, governance and disclosure rules a company must meet to have its shares traded on the NASDAQ stock exchange. Think of them as the standards a business must pass to join an exclusive marketplace — they affect whether a stock can be bought easily, how much public information the company must provide, and how investors judge its credibility and risk. Meeting these rules can boost liquidity and investor confidence.

market value of publicly held shares financial

"including those related to market value of publicly held shares and other continued listing standards."

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

cell and gene therapy medical

"its strategic mineral resources and cell and gene therapy assets."

Therapies that use living cells or altered genes to treat or cure disease by repairing, replacing or reprogramming parts of the body; think of it as swapping or reprogramming malfunctioning hardware or software inside the body. Investors watch these treatments closely because they can command high prices and offer one-time or long-lasting benefits, but they also carry big development costs, complex manufacturing and regulatory risks that can cause large swings in a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Extension reflects Company's continued compliance with all other applicable Nasdaq listing requirements

CHARLOTTE, N.C., March 23, 2026 /PRNewswire/ -- Greenland Mines Ltd (Nasdaq: GRML) ("Greenland Mines" or the "Company") today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") granting the Company an additional 180-day period, through September 14, 2026, to regain compliance with Nasdaq's minimum bid price requirement.

The extension reflects Nasdaq's determination that the Company meets all other applicable listing requirements, including those related to market value of publicly held shares and other continued listing standards.

As previously disclosed, the Company must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the compliance period to regain compliance with Nasdaq's requirements.

Greenland Mines remains committed to maintaining its Nasdaq listing and advancing the development of its strategic mineral resources and cell and gene therapy assets.

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices. The Company is led by an experienced team of mining, geological, biotech, and capital markets professionals.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

The Mineral Resource Estimates referenced in this press release were prepared in accordance with NI 43-101 by SLR Consulting as disclosed in the technical report dated November 22, 2022. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The gross undiscounted in-situ metal values expressed herein are illustrative calculations using February 2026 metal prices and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or any other technical or economic factors. These values are not indicative of future revenue, project economics or net present value. No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project, and there is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.

Investor Contact and Corporate Communications:
ir@greenlandmines.com

Website: www.greenlandmines.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenland-mines-secures-additional-180-day-period-for-nasdaq-bid-price-compliance-302721430.html

SOURCE Greenland Mines Ltd

FAQ

What did Greenland Mines (GRML) announce about Nasdaq bid-price compliance on March 23, 2026?

Greenland Mines announced Nasdaq granted a 180-day extension through September 14, 2026. According to the company, Nasdaq determined it meets other listing standards while remaining below the minimum bid-price requirement.

How does Greenland Mines (GRML) regain compliance with Nasdaq's minimum bid price?

The company must achieve a $1.00 closing bid for 10 consecutive business days during the extension. According to the company, that condition is required within the current compliance period to avoid delisting.

How long is the Nasdaq compliance extension granted to Greenland Mines (GRML)?

Nasdaq granted an additional 180-day compliance period ending on September 14, 2026. According to the company, this extension follows Nasdaq's review of other continued listing requirements.

Does the Nasdaq extension mean Greenland Mines (GRML) meets other listing requirements?

Yes. Nasdaq determined Greenland Mines meets other applicable listing standards, including market value of publicly held shares. According to the company, only the minimum bid-price standard remains noncompliant.

What happens if Greenland Mines (GRML) fails to meet the $1.00 bid-price by September 14, 2026?

Failure to meet the requirement could prompt Nasdaq to begin delisting proceedings for the company. According to the company, regaining the $1.00 closing bid for 10 consecutive business days avoids that outcome.